Most patients with relapsing-remitting MS who are stable on natalizumab every 4 weeks, can switch to a 6-week dosing regimen without losing efficacy, according to results of a clinical trial published in the Lancet Neurology.
“Extension of the natalizumab dosing interval to longer than 4 weeks has been suggested as a possible means to reduce risk of progressive multifocal leukoencephalopathy, potentially by allowing limited CNS immune surveillance to return without the disease activity associated with treatment interruption,” John F. Foley, MD, of the Rocky Mountain MS Clinic in
Longer dosing intervals of natalizumab safe, effective for MS patients
Most patients with relapsing-remitting MS who are stable on natalizumab every 4 weeks, can switch to a 6-week dosing regimen without losing efficacy, according to results of a clinical trial published in the Lancet Neurology.
“Extension of the natalizumab dosing interval to longer than 4 weeks has been suggested as a possible means to reduce risk of progressive multifocal leukoencephalopathy, potentially by allowing limited CNS immune surveillance to return without the disease activity associated with treatment interruption,” John F. Foley, MD, of the Rocky Mountain MS Clinic in